. 2023 Nov 18;13:20213. doi: 10.1038/s41598-023-47611-w

Table 3.

Comparison of antibody titers after the first and second dose of COV2-vaccinations.

Vaccine type	Titer1^a (n = 462)	P-value	Titer2^b (n = 301)	P-value
Vaccine type	Median (IQR 25–75)	P-value	Median (IQR 25–75	P-value
AstraZeneca	224.0 (68.8–396.8)	< 0.001	377.6 (275.2–416.0)	< 0.001
COVIran Barekat	105.6 (16.0–284.8)		192.0 (72.0–297.6)
Sinopharm	91.2 (16.0–276.8)		195.2 (73.6–302.4)

IQR, interquartile range; ^a; antibody titer (BAU/ml) before the second dose of vaccination; ^b; antibody titer (BAU/ml) 1 month after the second dose of vaccination. Significance values have been adjusted by the Bonferroni correction for multiple tests (Sinopharmm-COVIran Barekat 1.000, Sinopharm-AstraZeneca < 0.001, COVIran Barekat-AstraZeneca < 0.001) for both of measurements.